Verrica Pharmaceuticals completes enrollment in COVE-2 Phase 3 trial
Verrica Pharmaceuticals (VRCA) completed enrollment in the first pivotal Phase 3 trial (COVE-2) of YCANTH for common warts; topline data expected Q1 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.